Eyeing a $6B market, Bavarian Nordic posts positive phase 2 data for universal RSV vaccine
admin 27th June 2017 Uncategorised 0Chasing a big market opportunity that recently tripped up another vaccine developer, Bavarian Nordic reports that a single shot of its universal (RSV) candidate can elicit a significant immune response shortly after vaccination.
More: Eyeing a B market, Bavarian Nordic posts positive phase 2 data for universal RSV vaccine
Source: fierce